A5045385519- Liver Disease Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Multiple and Secondary Primary Cancers
- Genetic and Kidney Cyst Diseases
- Liver Disease and Transplantation
- Renal Transplantation Outcomes and Treatments
- Healthcare Systems and Challenges
- Hepatocellular Carcinoma Treatment and Prognosis
- Organ Transplantation Techniques and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Research Studies
- Liver physiology and pathology
- Vascular anomalies and interventions
- Metabolism and Genetic Disorders
- Neuroendocrine Tumor Research Advances
- Tuberous Sclerosis Complex Research
- Drug Transport and Resistance Mechanisms
- PI3K/AKT/mTOR signaling in cancer
- Hepatitis Viruses Studies and Epidemiology
- Liver Diseases and Immunity
- Neuroblastoma Research and Treatments
- Cancer Genomics and Diagnostics
- Transplantation: Methods and Outcomes
Emory University
2019-2024
Cornell University
2019
Hadassah Medical Center
2019
Emory University Hospital
2018
University of Pennsylvania
2017
St. Jude Medical Center
2017
Massachusetts General Hospital
2014
Harvard University
2014
Adherence to the American Association for Study of Liver Disease (AASLD) guidelines management chronic hepatitis B (CHB) has not been systematically assessed. We sought comprehensively evaluate adherence five key areas these guidelines. also evaluated physician and patient factors underlying nonadherence, predictors nonadherence such as type, demographic factors, phase CHB infection.Nine hundred sixty-two adult patients were retrospectively identified. Each chart was reviewed in detail. The...
Cardiovascular disease is a leading cause of death among liver transplant (LT) recipients. With rising burden posttransplantation metabolic disease, increases in cardiovascular-related morbidity and mortality may reduce life expectancy after LT. It unknown if the risk long-term major cardiovascular events (MCEs) differs LT recipients with varying diabetic states. We performed retrospective cohort study from 2003 through 2013 to compare incidence MCEs patients (1) without diabetes, (2)...
<b><i>Introduction:</i></b> Fibrolamellar carcinoma (FLC) is a rare liver cancer that predominantly affects younger patients without history of disease. Surgical resection the cornerstone therapy and represents best potentially curative treatment option. Modest objective responses with cytotoxic chemotherapy alone or combined immune checkpoint inhibitors (ICIs) have been reported; however, there are no established systemic regimens for unresectable metastatic FLC....
Liver transplantation offers the best survival for patients with early-stage hepatocellular carcinoma (HCC). Prior studies have demonstrated disparities in transplant access; none examined early steps of process. We identified determinants access to referral and evaluation among HCC a single tumor either within Milan or meeting downstaging criteria Georgia.Population-based cancer registry data from 2010 2019 were linked liver centers Georgia. Primary cohort: adult ≤8 cm diameter, no...
The aim of this study was to analyze in a retrospective cohort the outcomes United States-based group metastatic neuroendocrine tumor (NET) patients who underwent peptide receptor radionuclide therapy (PRRT).Twenty-eight from single US NET Center were treated with PRRT. Toxicities assessed using Common Terminology Criteria for Adverse Events version 4.03. Progression determined by Response Evaluation Solid Tumors 1.1. Univariate and multivariate Cox regression performed identify potential...
Posttransplant diabetes mellitus (PTDM), an increasingly recognized complication of solid organ transplantation, is associated with increased morbidity and mortality following liver transplantation (LT). Hepatitis C virus (HCV) infection a consistent modifiable risk factor for PTDM. Prior studies have demonstrated improvement in glucose metabolism sustained virological response (SVR). However, the effect SVR on incidence PTDM has not been previously investigated large cohort LT recipients....
TPS578 Background: Liver transplantation is a curative treatment option in hepatocellular carcinoma (HCC) however; up to 20% of patients develop recurrent disease. HCC recurrence post-transplant usually extrahepatic (up 67%) hence requires effective systemic therapy options. Available data are limited and restricted small non-randomized studies case series. Lack prospective clinical trial indicates an area unmet need after liver transplantation. This phase II study aims evaluate the safety...
<div>Abstract<p>Liver transplantation offers the best survival for patients with early-stage hepatocellular carcinoma (HCC). Prior studies have demonstrated disparities in transplant access; none examined early steps of process. We identified determinants access to referral and evaluation among HCC a single tumor either within Milan or meeting downstaging criteria Georgia.</p><p>Population-based cancer registry data from 2010 2019 were linked liver centers Georgia....
<p>Multivariable adjusted probability of transplant referral, evaluation initiation, and completion among patients with early-stage HCC in Georgia, accounting for non-transplant cancer treatment death as competing risks</p>
<p>Multivariable adjusted probability of transplant referral, evaluation initiation and completion among HCC patients in Georgia accounting for death as a competing risk</p>
<p>Liver transplant referral and evaluation among patients diagnosed with early-stage HCC in Georgia, 2010–2019.</p>
<p>Defining the early-stage HCC cohort—inclusion and exclusion of patients diagnosed in Georgia, 2010–2019.</p>
<p>Distribution of demographic and clinical characteristics among HCC patients diagnosed in Georgia (2010 – 2019)</p>
<p>Liver transplant referral and evaluation among Georgia HCC patients identified in the expanded cohort (2010 – 2019)</p>
<p>Multivariable adjusted probability of transplant referral, evaluation initiation, and completion among patients with early-stage HCC in Georgia, accounting for death as a competing risk</p>
<p>Characteristics of patients with early-stage HCC transplanted at a Georgia transplant center versus those outside (<i>n</i> = 191)</p>
<p>Multivariable adjusted probability of transplant referral, evaluation initiation, and completion among patients with early-stage HCC in Georgia, accounting for death as a competing risk</p>
<p>Distribution of demographic and clinical characteristics among patients with early-stage HCC diagnosed in Georgia (2010–2019)</p>
<p>Associations between early-stage HCC patient characteristics and liver transplant referral in Georgia (<i>n</i> = 1,379)</p>
<p>Associations between early-stage HCC patient characteristics and liver transplant referral in Georgia (<i>n</i> = 1,379)</p>
<p>Multivariable adjusted probability of transplant referral, evaluation initiation, and completion among patients with early-stage HCC in Georgia, accounting for non-transplant cancer treatment death as competing risks</p>
<p>Distribution of demographic and clinical characteristics among HCC patients diagnosed in Georgia (2010 – 2019)</p>
<p>Defining the early-stage HCC cohort—inclusion and exclusion of patients diagnosed in Georgia, 2010–2019.</p>
<p>Characteristics of patients with early-stage HCC transplanted at a Georgia transplant center versus those outside (<i>n</i> = 191)</p>